Xeloda Wins EU Approval for Adjuvant Therapy for Colon Cancer

Roche announced that the European authorities have approved Xeloda (capecitabine), an innovative oral chemotherapy, to be used as an adjuvant treatment (post-surgery) for colon cancer. Patients will now have the choice of an effective, convenient chemotherapy that prolongs cancer free life, with a less serious side effect profile compared to the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV).

Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=22123&nfid=rssfeeds)